CL2021002855A1 - Métodos de fabricación y polimorfos de un agente antihiperalgésico de tiazolina - Google Patents

Métodos de fabricación y polimorfos de un agente antihiperalgésico de tiazolina

Info

Publication number
CL2021002855A1
CL2021002855A1 CL2021002855A CL2021002855A CL2021002855A1 CL 2021002855 A1 CL2021002855 A1 CL 2021002855A1 CL 2021002855 A CL2021002855 A CL 2021002855A CL 2021002855 A CL2021002855 A CL 2021002855A CL 2021002855 A1 CL2021002855 A1 CL 2021002855A1
Authority
CL
Chile
Prior art keywords
thiazoline
polymorphs
manufacturing methods
antihyperalgesic
compound
Prior art date
Application number
CL2021002855A
Other languages
English (en)
Inventor
Scott L Dax
Original Assignee
Cersci Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cersci Therapeutics Inc filed Critical Cersci Therapeutics Inc
Publication of CL2021002855A1 publication Critical patent/CL2021002855A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento se proporcionan métodos para preparar un Compuesto 1 antihiperalgésico de tiazolina y polimorfos del mismo. Los métodos descritos en el presente documento usan reactivos económicos y son capaces de proporcionar el Compuesto 1 en cantidades a escala comercial. También se proporcionan composiciones farmacéuticas del Compuesto 1 adecuadas para la administración humana. (I)
CL2021002855A 2019-05-10 2021-10-29 Métodos de fabricación y polimorfos de un agente antihiperalgésico de tiazolina CL2021002855A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962846096P 2019-05-10 2019-05-10

Publications (1)

Publication Number Publication Date
CL2021002855A1 true CL2021002855A1 (es) 2022-06-17

Family

ID=70057356

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002855A CL2021002855A1 (es) 2019-05-10 2021-10-29 Métodos de fabricación y polimorfos de un agente antihiperalgésico de tiazolina

Country Status (14)

Country Link
US (2) US11161826B2 (es)
EP (1) EP3966200A1 (es)
JP (1) JP2022531453A (es)
KR (1) KR20220006539A (es)
CN (1) CN113874360A (es)
AU (1) AU2020275683A1 (es)
BR (1) BR112021022478A2 (es)
CA (1) CA3136102A1 (es)
CL (1) CL2021002855A1 (es)
CO (1) CO2021014873A2 (es)
IL (1) IL287776A (es)
MX (1) MX2021013524A (es)
SG (1) SG11202110561XA (es)
WO (1) WO2020231496A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2581063B1 (fr) 1985-04-30 1987-07-17 Chauvin Blache Lab Amino-2 thiazoles n-substitues, leur procede de preparation et leur application en therapeutique
US5840739A (en) 1992-11-16 1998-11-24 University Of Florida Research Foundation, Inc. Thiazoline acid derivatives
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
GB0508463D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
CN101528728B (zh) * 2006-08-03 2014-01-01 罗塔药品股份有限公司 6-1h-咪唑并-喹唑啉和喹啉衍生物，镇痛剂和抗炎剂
TW200826937A (en) 2006-11-01 2008-07-01 Astrazeneca Ab New use
NL2003786C2 (en) 2009-11-11 2010-07-30 Medner B V COMPOSITION FOR TOPICAL APPLICATION, USES THEREOF, APPLICATOR DEVICE AND KIT OF PARTS.
WO2011112602A1 (en) 2010-03-10 2011-09-15 Galleon Pharmaceuticals, Inc. Analgesic compounds, compositions, and uses thereof
EP3070084A1 (en) 2015-03-18 2016-09-21 Rottapharm Biotech S.r.l. New fyn kinase inhibitors
EP3548470B1 (en) 2016-12-01 2023-11-01 Promega Corporation 5,5-disubstituted luciferins and their use in luciferase-based assays

Also Published As

Publication number Publication date
CN113874360A (zh) 2021-12-31
WO2020231496A1 (en) 2020-11-19
MX2021013524A (es) 2021-12-10
US20220267285A1 (en) 2022-08-25
EP3966200A1 (en) 2022-03-16
US11161826B2 (en) 2021-11-02
BR112021022478A2 (pt) 2022-01-25
IL287776A (en) 2022-01-01
US20200354328A1 (en) 2020-11-12
CO2021014873A2 (es) 2022-01-28
CA3136102A1 (en) 2020-11-19
KR20220006539A (ko) 2022-01-17
SG11202110561XA (en) 2021-10-28
JP2022531453A (ja) 2022-07-06
AU2020275683A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
DOP2023000016A (es) Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos
CO2020001823A2 (es) Conjugados de citoquina para el tratamiento de enfermedades autoinmunes
UY37201A (es) Nuevos derivados de pirazolopirimidina
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
NI202000080A (es) Inhibidores de magl
BR112017000169A2 (pt) picolinamidas macrocíclicas como fungicidas
PE20181346A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer
CO2020001242A2 (es) Dihidrooxadiazinonas
UY35293A (es) Isotiazoles sustituidos con amino
ECSP20013332A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
CL2015002835A1 (es) Nuevos derivados de piridina
CL2020000944A1 (es) Compuestos bicíclicos y métodos de utilización de los mismos.
MX2020003495A (es) Derivados de acido boronico y sintesis de los mismos.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CR20170102A (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
BR112018070374A2 (pt) dispositivos para a aplicação de tampão médico com um magazine giratório e componentes e métodos relacionados
CO2019006017A2 (es) Composiciones farmacéuticas que contienen insulina
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
DOP2020000039A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
UY38809A (es) Derivados de 3,6-diamino-piridazin-3ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CY1122829T1 (el) Φαρμακευτικη συνθεση για νευροπαθητικο πονο